Steven Mitchell Cohen named director of robotic pancreas surgery at Northwell

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Steven Mitchell Cohen

Steven Mitchell Cohen was named director of robotic pancreas surgery at the Northwell Health Cancer Institute. 

Cohen, an expert in robotic Whipple procedures, will report to Matthew J. Weiss, vice president and vice chair of surgical service line, deputy physician-in-chief, and director of surgical oncology at Northwell Cancer Institute.

“The Whipple operation is already performed in high volume both robotically and open at Northwell Health,” Weiss said in a statement. “We’re confident Dr. Cohen will take this program to the next level.”

Prior to joining Northwell, Cohen served in roles at NYU Langone, from its gastrointestinal cancer management group to general surgery, as well as his involvement in Surgical Oncology NYC Health + Hospitals/Bellevue and NY Harbor VA Health Care System. 

Over the past five years, he focused extensively on robotic Whipple surgery in the Division of Hepatobiliary and Pancreatic Surgery. Cohen is board certified in general surgery and surgical critical care/trauma by the American Board of Surgery.

“The goal is to convert the more complicated pancreas surgeries to robotic procedures,” Cohen said in a statement. 

“Robotic pancreas Whipple surgery is preferable because it’s less invasive, there’s less blood loss, and patients will experience less pain post-op. The robot allows for a great deal of suturing and stitching, similar to what I can do during an open surgery. And the visual is very impressive since you can see it in 3D,” Cohen said. “Additionally, the patient’s hospital stay will be shorter, and they’ll experience a slightly shorter healing process.”

Cohen will perform robotic Whipple procedures at Long Island Jewish Medical Center in New Hyde Park, Lenox Hill Hospital in Manhattan, and South Shore University Hospital in Bay Shore.

Table of Contents

YOU MAY BE INTERESTED IN

Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login